GlassScriptPhysician profile
Jacob R Hopping
NPI 1538471099
$19,158.58
in general payments reported to CMS, 2019-2025
27 companies · $6,344 in 2025
The $6,344 reported for 2025 was more than what 92% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $8,746 · 2021: $625 · 2022: $290 · 2023: $1,790 · 2024: $607 · 2025: $6,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Consulting Fee: $2,000 · Food and Beverage: $1,798 · Travel and Lodging: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Consulting Fee | $2,000.00 |
| Food and Beverage | $1,797.64 |
| Travel and Lodging | $944.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,541.94 | 2019-2025 | |
| Origami Surgical INC | $2,000.00 | 2025 | Stitchkit |
| Medtronic, INC. | $1,378.67 | 2022-2024 | Pivox Oblique Lateral Spinal System, Navlock, Mazor X System |
| Davol INC. | $586.62 | 2021-2025 | Phasix Mesh |
| Boston Scientific Corporation | $349.29 | 2021-2023 | Spyglass Discover |
| Ethicon US, LLC | $258.35 | 2020-2025 | Echelon Flex, Enseal X1, Echelon Endopath |
| Covidien LP | $147.74 | 2019-2020 | |
| Conmed Corporation | $127.06 | 2024 | Airseal |
| Takeda Pharmaceuticals U.S.A., INC. | $112.39 | 2020-2024 | Gattex, Eohilia |
| Medical Device Business Services, INC. | $91.78 | 2019 | |
| Organogenesis INC. | $56.11 | 2019-2024 | Puraply, Puraply Franchise |
| Polynovo North America LLC | $54.43 | 2021-2023 | |
| Janssen Biotech, INC. | $48.13 | 2024-2025 | Simponi, Simponi Aria, Tremfya |
| Tei Biosciences INC | $47.90 | 2019 | |
| Myriad Genetic Laboratories, INC. | $44.80 | 2022-2023 | Myrisk |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $43.86 | 2023 | Stravix |
| Novo Nordisk INC | $41.02 | 2022-2024 | Wegovy |
| Endo Pharmaceuticals INC. | $37.23 | 2020-2021 | |
| Abbvie INC. | $33.96 | 2024 | |
| Cook Medical LLC | $27.31 | 2025 | Zilver Ptx |
| Pacira Pharmaceuticals Incorporated | $26.41 | 2023 | Exparel |
| Bolder Surgical LLC | $21.10 | 2020-2021 | |
| Orphalan INC | $18.84 | 2024 | Cuvrior |
| Nestle Healthcare Nutrition INC. | $17.75 | 2021 | |
| Baudax Bio INC. | $15.70 | 2020 | |
| Depuy Synthes Sales INC. | $15.55 | 2019 | |
| Kci USA, INC. | $14.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Hopping listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.